(a) The board shall hold a public meeting quarterly at the call of the presiding officer and shall permit public comment before voting on any changes in the preferred drug lists the commission adopts under Subchapter E, the adoption of or changes to drug use criteria, or the adoption of prior authorization or drug utilization review proposals. The location of the quarterly public meeting may rotate among different geographic areas across this state, or allow for public input through teleconferencing centers in various geographic areas across this state.
(b) The board shall hold public meetings at other times at the call of the presiding officer.

(c) Minutes of each meeting shall be made available to the public not later than the 10th business day after the date the minutes are approved.
(d) The board may meet in executive session to discuss confidential information as described by § 549.0308.
(e) Board members appointed under § 549.0302(a)(1) may attend quarterly and other regularly scheduled meetings, but may not:
(1) attend executive sessions; or
(2) access confidential drug pricing information.
(f) In this subsection, “labeler” and “manufacturer” have the meanings assigned by § 549.0101. The commission shall ensure that a drug that has been approved or had any of the drug’s particular uses approved by the United States Food and Drug Administration under a priority review classification is reviewed by the board at the next regularly scheduled board meeting. On receiving notice from a manufacturer or labeler of the availability of a new product, the commission, to the extent possible, shall schedule a review for the product at the next regularly scheduled board meeting.

Text of section effective on April 01, 2025